清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Efficacy and safety of dupilumab plus topical tacrolimus for atopic dermatitis in 6- to 12-year-old patients.

杜皮鲁玛 湿疹面积及严重程度指数 特应性皮炎 医学 他克莫司 不利影响 内科学 皮肤病科 免疫球蛋白E 胃肠病学 抗体 免疫学 移植
作者
S-S Gao,M Chen,R Wang,J-G Chen
出处
期刊:PubMed [National Institutes of Health]
卷期号:27 (20): 9830-9837 被引量:3
标识
DOI:10.26355/eurrev_202310_34159
摘要

OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of combining dupilumab with topical tacrolimus for the treatment of atopic dermatitis (AD) in children aged 6 to 12 years. PATIENTS AND METHODS: A total of 168 pediatric (aged 6 to 12 years) patients with severe AD admitted to our hospital between April 2022 and April 2023 were included in this retrospective study. These patients are grouped according to different medication methods, assigned them to receive either tacrolimus plus topical corticosteroids (control group) or dupilumab combined with tacrolimus and topical corticosteroids (study group), with 84 patients in each group. Clinical efficacy and adverse reactions were primary clinical endpoints. RESULTS: The use of dupilumab significantly increased the total effective rate for the patients by 14.29%, from 77.38% (65/84) in the control group to 91.67% (77/84) in the study group. Following treatment, patients given dupilumab showed a more significantly decreased peripheral blood eosinophils (EOS) and immunoglobulin E (IgE) levels than those without dupilumab treatment. Patients administered with dupilumab exhibited markedly lower scores on the Patient-oriented Eczema Measure (POEM) at weeks 12 and 16 and lower Eczema Area and Severity Index (EASI) scores at weeks 8, 12, and 16 when compared to those patients who did not receive dupilumab therapy. At the 16-week, 37 patients in the study group obtained a score of 1/0 on the Verified Investigator's Global Assessment (v-IGA) scale, whereas the control group had 24 such cases, indicating a significantly higher response rate provided by the protocol incorporating dupilumab. After 16 weeks of treatment, both groups demonstrated a marked decrease in itch numeric rating scale (NRS) scores and Dermatology Life Quality Index (DLQI) scores, with lower scores observed in the study group than in the control group. The absence of a significant difference in the incidence of adverse reactions between the two groups suggested a high safety profile of dupilumab. CONCLUSIONS: The combination of dupilumab with topical tacrolimus demonstrated favorable efficacy in the management of AD in children aged 6 to 12 years. This treatment protocol effectively alleviates symptoms, enhances the quality of life of patients, and shows no increased risk of adverse reactions.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
微笑妖丽完成签到,获得积分10
2秒前
qin完成签到 ,获得积分10
5秒前
mzhang2完成签到 ,获得积分10
13秒前
wwwwwnnnnn完成签到 ,获得积分10
17秒前
英俊的铭的应助被科研通管家采纳,获得10
19秒前
21秒前
沙海沉戈完成签到,获得积分0
21秒前
彩色听筠完成签到,获得积分10
39秒前
复杂的雁芙完成签到,获得积分10
42秒前
领导范儿的应助被BYL采纳,获得10
44秒前
45秒前
成就云朵完成签到,获得积分10
1分钟前
1分钟前
晓晓完成签到,获得积分10
1分钟前
晓晓发布了新的文献求助10
1分钟前
lulu完成签到,获得积分10
1分钟前
韦韦完成签到 ,获得积分10
1分钟前
李木禾完成签到 ,获得积分10
1分钟前
vbnn完成签到 ,获得积分10
1分钟前
1分钟前
Husile发布了新的文献求助10
1分钟前
迷人悒完成签到,获得积分10
1分钟前
huluwa完成签到,获得积分10
1分钟前
1分钟前
YZY完成签到 ,获得积分10
1分钟前
1分钟前
坚强冷荷完成签到,获得积分10
1分钟前
风中碧菡完成签到,获得积分10
1分钟前
BYL发布了新的文献求助10
1分钟前
Husile完成签到,获得积分10
1分钟前
文静飞松完成签到,获得积分10
1分钟前
1分钟前
1分钟前
kk完成签到 ,获得积分10
2分钟前
lCJ发布了新的文献求助10
2分钟前
古炮完成签到 ,获得积分10
2分钟前
踏实的西牛完成签到,获得积分10
2分钟前
Cakoibao完成签到,获得积分10
2分钟前
我是老大的应助被lCJ采纳,获得10
2分钟前
可爱沛蓝完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179980
求助须知:如何正确求助?哪些是违规求助? 9570196
关于积分的说明 21808506
捐赠科研通 7775966
什么是DOI,文献DOI怎么找? 3433251
关于科研通互助平台的介绍 2557389
邀请新用户注册赠送积分活动 2478998